Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
KLBK Lubbock on MSN22h
FTC report highlights prescription drug pricing issues in LubbockPrescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback